Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1136/archdischild-2024-327921 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A Retrospective Study in Trans Individuals Undergoing Gender Affirming Testosterone Treatment: Can Changes in Prolactin Counteract the Negative Effects on the Lipid Profile?
Biomedicines
December 2024
Clinical Division of Gynecologic Endocrinology and Reproductive Medicine, Medical University of Vienna, A-1090 Vienna, Austria.
Gender-affirming hormone therapy (GAHT) is known to influence the lipid profiles of trans men and transmasculine individuals. Recent data show that moderate prolactin (PRL) elevations might exert beneficial metabolic effects ("HomeoFIT-PRL model"). The aim of this study is to investigate changes in PRL levels and possible associations between PRL and lipid profiles in this population after a year of GAHT.
View Article and Find Full Text PDFGender-affirming hormone therapy for individuals with gender dysphoria below 26 years of age: A systematic review and meta-analysis.
Arch Dis Child
January 2025
Health Research Methodology, McMaster University Faculty of Health Sciences, Hamilton, Ontario, Canada.
Fertility in transgender and gender diverse people: systematic review of the effects of gender-affirming hormones on reproductive organs and fertility.
Hum Reprod Update
January 2025
Amsterdam UMC, Location Vrije Universiteit Amsterdam, Centre of Expertise on Gender Dysphoria, Amsterdam, The Netherlands.
Background: Transgender and gender diverse (TGD) people seek gender-affirming care at any age to manage gender identities or expressions that differ from their birth gender. Gender-affirming hormone treatment (GAHT) and gender-affirming surgery may alter reproductive function and/or anatomy, limiting future reproductive options to varying degrees, if individuals desire to either give birth or become a biological parent.
Objective And Rationale: TGD people increasingly pursue help for their reproductive questions, including fertility, fertility preservation, active desire for children, and future options.
Artificial intelligence evaluation of electrocardiographic characteristics and interval changes in transgender patients on gender-affirming hormone therapy.
Eur Heart J Digit Health
January 2025
Department of Cardiovascular Medicine, Mayo Clinic, 200 1st St SW, Rochester, MN 55905, USA.
Aims: Gender-affirming hormone therapy (GAHT) is used by some transgender individuals (TG), who comprise 1.4% of US population. However, the effects of GAHT on electrocardiogram (ECG) remain unknown.
View Article and Find Full Text PDFReevaluating gender-affirming care: biological foundations, ethical dilemmas, and the complexities of gender dysphoria.
J Sex Marital Ther
January 2025
Department of Interdisciplinary Studies, University of South Florida, Tampa, FL, USA.
This paper critically examines the scientific and ethical underpinnings of gender-affirming care, particularly for minors. While major medical organizations endorse such interventions as medically necessary, the evidence supporting their long-term safety and efficacy remains limited. Research into hormonal, neuroanatomic, and genetic influences reveals a strong biological basis for gender identity, challenging social constructionist arguments.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!